Brands, Medical Use, Clinical Data
Drug Category
Dosage Forms
- Capsule
- Liquid
- Metered-dose (aerosol)
- Ointment
- Powder
- Solution
- Spray
Brands / Synonyms
Aarane; Acide Cromoglicique [Inn-French]; Acido Cromoglicico [Inn-Spanish]; Acidum Cromoglicicum [Inn-Latin]; Alercom; Alerion; Allergocrom; Apo-Cromolyn; Children's Nasalcrom; Colimune; Crolom; Cromoglicic Acid; Cromoglycic Acid; Cromolyn; Cromolyn Nasal Solution; Cromolyn Sodium; Cromoptic; Cromovet; Diethyl Cromoglycicate; Fivent; Gastrocrom; Gastrofrenal; Gen-Cromoglycate; Inostral; Intal; Intal Inhaler; Intal Syncroner; Introl; Irtan; Lomudal; Lomupren; Lomusol; Lomuspray; Nalcrom; Nalcron; Nasalcrom; Nasmil; Novo-Cromolyn; Opticrom; Opticron; Pms-Sodium Cromoglycate; Rynacrom; Sodium Cromoglycate; Sofro; Vistacrom; Vividrin
Indications
For the management of patients with bronchial asthma. Also used in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
Pharmacology
Cromolyn, a synthetic compound, inhibits antigen-induced bronchospasms and, hence, is used to treat asthma and allergic rhinitis. Cromolyn is used as an ophthalmic solution to treat conjunctivitis and is taken orally to treat systemic mastocytosis and ulcerative colitis.
Mechanism of Action
Cromolyn inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Cromolyn also may reduce the release of inflammatory leukotrienes. Cromolyn may act by inhibiting calcium influx.
Absorption
1%
Toxicity
cough, nasal congestion, nausea, sneezing and wheezing
Biotrnasformation / Drug Metabolism
Not Available
Contraindications
Intal Inhaler is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or other
ingredients in this preparation.
Drug Interactions
Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following
subcutaneous injections in pregnant mice. Cromolyn sodium alone in doses up to 540 mg/kg/day (approximately 340 times
the maximum recommended daily inhalation dose in adults on a mg/m2 basis) did not cause significant
increases in resorptions or major malformations. Isoproterenol alone at a dose of 2.7 mg/kg/day (approximately 7
times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) increased both resorptions
and malformations. The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended
daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times
the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the
incidence of both resorptions and malformations.
|